skip to content


AZ-Merck's Lynparza gets US approval for ovarian cancer

18 August 2017 07:14

AstraZeneca and Merck & Co have announced that Lynparza has received additional and broad approval in the US for ovarian cancer.

The said the US Food and Drug Administration (FDA) had granted approval for the PARP inhibitor, Lynparza (olaparib), as follows:

- New use of Lynparza as a maintenance treatment for recurrent, epithelial ovarian, fallopian tube or primary peritoneal adult cancer who are in response to platinum-based chemotherapy, regardless of BRCA status;

- New use of Lynparza tablets (2 tablets twice daily) as opposed to capsules (8 capsules twice daily);

- Lynparza tablets also now indicated (conversion from the current accelerated approval) for the use in patients with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer, who have been treated with three or more prior lines of chemotherapy. AstraZeneca executive vice-president, global medicines development and chief medical officer, Sean Bohen, said: "Physicians have almost three years of clinical experience with Lynparza on the market and we are now pleased to bring this important medicine, in a new tablet formulation, to a broader group of women.

"Today's approvals validate more than 10 years of dedicated research behind Lynparza, the world's first PARP inhibitor, which now provides oncologists with the greater flexibility for use in terms of treatment settings.

"It builds on our recently-announced collaboration with Merck, which aims to further increase the number of treatment options available to patients."

Story provided by

Related Company: AZN

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?


Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.